Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294328 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
A Phase 2 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 5
- Study locations
NCT05294328 is a Phase 2 study of Presbyopia and Eye Diseases that has completed, run by LENZ Therapeutics. The registered enrollment target is 68 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05294328, a Phase 2 study of Presbyopia and Eye Diseases, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 5
- Study locations
Study Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Conditions Studied
Interventions
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine ophthalmic solution
- DRUG Vehicle Proprietary Ophthalmic Solution
Study Locations (5)
California
- INSIGHT-1 Study Site #4 - Glendale
Indiana
- INSIGHT-1 Study Site #3 - Indianapolis
Massachusetts
- INSIGHT-1 Study Site #1 - Andover
Tennessee
- INSIGHT-1 Study Site #2 - Memphis
Texas
- INSIGHT-1 Study Site #5 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2022-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05294328
The ClinicalTrials.gov registry entry for NCT05294328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (75% lower). The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Aceclidine+Brimonidine combination ophthalmic solution is the first listed.
NCT05294328 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05294328 about?
NCT05294328 is a clinical study titled "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia". To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
What is the current status of trial NCT05294328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-05-05. Estimated completion is 2022-09-10.
What conditions does trial NCT05294328 study?
This clinical trial studies the following conditions: Presbyopia, Eye Diseases, Refractive Errors.
What interventions are being tested in trial NCT05294328?
The interventions under investigation include: Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine ophthalmic solution (DRUG), Vehicle Proprietary Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05294328?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05294328 being conducted?
This trial has 5 study locations across California, Indiana, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
COMPLETED · Phase 2
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Comfort and Vision With TOTAL30 Multifocal Lenses
RECRUITING
-
North American Comfilcon A Clinical Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.